Morgan Stanley Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on Edwards Lifesciences (NYSE:EW) but has reduced the price target from $102 to $80.
December 04, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Edwards Lifesciences but lowered the price target from $102 to $80.
The reduction in price target by Morgan Stanley, despite maintaining an Overweight rating, could lead to a negative perception among investors, potentially causing short-term downward pressure on the stock price of Edwards Lifesciences.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100